Max Chat
Share chart J. B. Chemicals & Pharmaceuticals Limited
Extended chart
Simple chart
About J. B. Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.Main settings
ISIN
INE572A01028
Industry
Pharmaceuticals
Sector
Health Care
Валюта
inr
Валюта отчета
inr
Див.доход ао
0.6872
Дивиденд ао
15.25
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 7.25 | 1 |
| P/BV | 8.55 | 1 |
| P/E | 45.21 | 3 |
Efficiency
| Title | Value | Grade |
| ROA | 14.64 | 4 |
| ROE | 20.45 | 7 |
| ROIC | 18.72 | 6 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0.729 | 1.83 |
| DSI | 0.8571 | 8.57 |
| Average dividend growth | 11.7 | 10 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 0.124 | 10 |
| Debt/Ratio | 0.0894 | 10 |
| Debt/Equity | 0.3663 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 97.83 | 9 |
| Yield Ebitda, % | 731 | 10 |
| Yield EPS, % | 106.67 | 10 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 1 732.05 ₹ | 0 ₹ | 0 ₹ | 0 % | 0 % | 0 % |
| Week | 1 676.75 ₹ | 0 ₹ | 0 ₹ | 3.3 % | 0 % | 0 % |
| Month | 1 702.45 ₹ | 1 666.55 ₹ | 1 745.1 ₹ | 1.74 % | 0 % | 0 % |
| Three month | 1 541.55 ₹ | 1 503.45 ₹ | 1 745.1 ₹ | 12.36 % | 0 % | 0 % |
| Half a year | 1 712.3 ₹ | 1 503.45 ₹ | 1 899.9 ₹ | 1.15 % | 0 % | 0 % |
| Year | 1 960.6 ₹ | 1 503.45 ₹ | 1 969.1 ₹ | -11.66 % | 0 % | 0 % |
| 3 years | 1 798.3 ₹ | 1 287.7 ₹ | 2 989 ₹ | -3.68 % | 0 % | 0 % |
| 5 years | 720.8 ₹ | 705.45 ₹ | 2 989 ₹ | 140.3 % | 0 % | 0 % |
| 10 years | 236.3 ₹ | 236.3 ₹ | 2 989 ₹ | 732.99 % | 0 % | 0 % |
| Year to date | 1 718.25 ₹ | 1 503.45 ₹ | 1 899.9 ₹ | 0.8 % | 0 % | 0 % |
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Nikhil Ashokkumar Chopra | CEO & Whole-Time Director | 65.45M | 1973 (52 years) |
| Mr. Kunal Khanna | President of Operations | N/A | 1980 (45 years) |
| Mr. Sridhar Bharadwaj | Vice President of HR & Administration | N/A | 1967 (58 years) |
| Mr. Pradeep Kumar Singh | President of Global Business | N/A | 1964 (61 year) |
| Mr. Himanshu Ranvah | Vice President of Legal | N/A | 1985 (40 years) |
| Mr. Parmeshwar B. Bang | Executive Vice President of Operations of Daman | N/A | 1968 (57 years) |
| Suresh Amin | Assistant Vice President ? Human Resource | ||
| Mr. Narayan Saraf | Chief Financial Officer | 1980 (45 years) | |
| Mr. Bhagwat Singh Deora | Vice President of Finance & Accounts | 1982 (43 years) | |
| Mr. Suresh Bhise | Vice President of Information & Technology | 1966 (59 years) |
About company
Address: India, Mumbai, Cnergy IT Park - Open in google maps, Open in yandex maps
Website: https://www.jbpharma.com
Website: https://www.jbpharma.com
